Viridian Therapeutics, Inc. VRDN Payment Of Issuance Costs, Sale Of Future Revenue
Payment Of Issuance Costs, Sale Of Future Revenue at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept vrdn:PaymentOfIssuanceCostsSaleOfFutureRevenue.
The official record: Viridian Therapeutics, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s payment of issuance costs, sale of future revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s payment of issuance costs, sale of future revenue?
- Viridian Therapeutics, Inc. (VRDN) reported payment of issuance costs, sale of future revenue of $1.25M in Q4 2025.
- What does payment of issuance costs, sale of future revenue mean?
- This represents the cash outflows incurred for transaction costs related to agreements where the company sells rights to future revenue streams in exchange for upfront capital. These costs are directly associated with non-dilutive financing structures often used by biopharmaceutical companies. It highlights the immediate cost of accessing capital through royalty or revenue-sharing arrangements.